Log in

Relevant bibliographies by topics / Minimal Residual Disease Detection / Books

Books on the topic 'Minimal Residual Disease Detection'

To see the other types of publications on this topic, follow the link: Minimal Residual Disease Detection.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 37 books for your research on the topic 'Minimal Residual Disease Detection.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

F, Zipf Theodore, and Johnston Dennis A, eds. Leukemia and lymphoma: Detection of minimal residual disease. Totowa, N.J: Humana Press, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Druley, Todd E., ed. Minimal Residual Disease Testing. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-94827-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Reinhold, Uwe, and Wolfgang Tilgen, eds. Minimal Residual Disease in Melanoma. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59537-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hagenbeek, Anton, and Bob Löwenberg, eds. Minimal Residual Disease in Acute Leukemia 1986. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4273-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Aguirre-Ghiso, Julio A., ed. Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-97746-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ignatiadis, Michail, Christos Sotiriou, and Klaus Pantel, eds. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-28160-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Zipf, Theodore F., and Dennis A. Johnston. Leukemia and Lymphoma: Detection of Minimal Residual Disease. Humana Press, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

F, Zipf Theodore, and Johnston Dennis A, eds. Leukemia and lymphoma: Detection of minimal residual disease. Totowa, N.J: Humana Press, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Leukemia and Lymphoma: Detection of Minimal Residual Disease. Humana Press, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Zipf, Theodore F., and Dennis A. Johnston. Leukemia and Lymphoma: Detection of Minimal Residual Disease. Humana Press, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Tilgen, W., and U. Reinhold. Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance. Springer London, Limited, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Tilgen, W., and U. Reinhold. Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance. Springer London, Limited, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

(Editor), U. Reinhold, and W. Tilgen (Editor), eds. Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance (Recent Results in Cancer Research). Springer, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Minimal Residual Disease in Leukaemia. Elsevier, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

Hagenbeek, A., and B. Löwenberg. Minimal Residual Disease in Acute Leukemia. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Hagenbeek, A., and B. Löwenberg. Minimal Residual Disease in Acute Leukemia. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Hagenbeek, A., and B. Löwenberg. Minimal Residual Disease in Acute Leukemia. Springer, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

L, Foroni, and Hoffbrand A. V, eds. Minimal residual disease investigation in haematological malignancies. London: Baillière Tindall, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

A, Hagenbeek, and Löwenberg B. 1946-, eds. Minimal residual disease in acute leukemia, 1986. Dordrecht: Nijhoff, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

Hagenbeek, A., and B. Löwenberg. Minimal Residual Disease in Acute Leukemia 1986. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Hagenbeek, A. Minimal Residual Disease in Acute Leukemia 1986. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

(Editor), Pia Raanani, and Andreas Hochhaus (Editor), eds. Minimal Residual Disease In Hematologic Malignancies (Acta Haematologica 2004). Not Avail, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Aguirre-Ghiso, Julio A. Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. Springer, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

Druley, Todd E. Minimal Residual Disease Testing: Current Innovations and Future Directions. Springer, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

Minimal Residual Disease And Circulating Tumor Cells In Breast Cancer. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

26

(Editor), A. Hagenbeek, and B. Löwenberg (Editor), eds. Minimal Residual Disease in Acute Leukemia 1986 (Developments in Oncology). Springer, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

Pantel, Klaus, Michail Ignatiadis, and Christos Sotiriou. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

28

Pantel, Klaus, Michail Ignatiadis, and Christos Sotiriou. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Springer London, Limited, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

29

Pantel, Klaus, Michail Ignatiadis, and Christos Sotiriou. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Springer Berlin / Heidelberg, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

30

Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II: Adjuvant Therapies of the Various Primary Tumors. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bonadonna, Gianni, and Georges Mathé. Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II: Adjuvant Therapies of the Various Primary Tumors. Brand: Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bonadonna, Gianni, G. Mathe, and S. E. Salmon. Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I: Markers and General Problems of Cancer Adjuvant Therapies. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

33

Clifford, Michael. Children with Congenital Heart Disease for Non-cardiac Surgery. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199764495.003.0030.

Full text

Abstract:

It is estimated that up to 1 million children in the United States have congenital heart disease (CHD). These children range from those who are essentially normal functionally with anatomically repaired hearts, and hence minimal impact for anesthesia, to those that have had complex and numerous surgical procedures with significant residual abnormalities in circulation and cardiac function, and a range of comorbidities. These latter children have many issues that will affect anesthesia for non-cardiac surgery. When presented with a child with CHD for non-cardiac surgery, the general pediatric anesthesiologist should be able to perform a tailored cardiac preoperative evaluation and plan an appropriate anesthetic with suitable anesthetic techniques, agents, and monitoring. Not every child with CHD has a single ventricle with all its complexity (see Chapter 31), but every child with CHD will offer challenges for the pediatric anesthesiologist.

APA, Harvard, Vancouver, ISO, and other styles

34

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Full text

Abstract:

The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.

APA, Harvard, Vancouver, ISO, and other styles

35

Bebell, Lisa M. Ebola and Other Filoviruses. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190604813.003.0002.

Full text

Abstract:

Congenital and pediatric Ebola virus disease (EVD) and Marburg virus disease (MVD) are severe, even lethal infections. Historically, children have been underrepresented in filovirus disease outbreaks, and evidence-based treatment strategies are lacking. Existing data suggest that case fatalities are highest among children under four years of age, which is partially explained by higher virus concentrations in young children. Prevention and aggressive resuscitation, nutrition, and supportive care are the mainstays of management until filovirus-specific therapies can be developed. Differences in pediatric immune and inflammatory responses may necessitate unique approaches to pediatric vaccination and treatment. There are minimal safety or immunogenicity data in children, a crucial knowledge gap that must be addressed in future trials. Studying pediatric survivors of the 2014–2016 West Africa EVD outbreak will provide much-needed data on long-term outcomes and residual effects of filovirus disease while we await effective filovirus-specific vaccines and therapies.

APA, Harvard, Vancouver, ISO, and other styles

36

Martin-Loeches, Ignacio, and Antonio Artigas. Respiratory support with positive end-expiratory pressure. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0094.

Full text

Abstract:

Positive-end-expiratory pressure (PEEP) is the pressure present in the airway (alveolar pressure) above atmospheric pressure that exists at the end of expiration. The term PEEP is defined in two particular settings. Extrinsic PEEP (applied by ventilator) and intrinsic PEEP (PEEP caused by non-complete exhalation causing progressive air trapping). Applied (extrinsic) PEEP—is usually one of the first ventilator settings chosen when mechanical ventilation (MV) is initiated. Applying PEEP increases alveolar pressure and volume. The increased lung volume increases the surface area by reopening and stabilizing collapsed or unstable alveoli. PEEP therapy can be effective when used in patients with a diffuse lung disease with a decrease in functional residual capacity. Lung protection ventilation is an established strategy of management to reduce and avoid ventilator-induced lung injury and mortality. Levels of PEEP have been traditionally used from 5 to 12 cmH2O; however, higher levels of PEEP have also been proposed and updated in order to keep alveoli open, without the cyclical opening and closing of lung units (atelectrauma). The ideal level of PEEP is that which prevents derecruitment of the majority of alveoli, while causing minimal overdistension; however, it should be individualized and higher PEEP might be used in the more severe end of the spectrum of patients with improved survival. A survival benefit for higher levels of PEEP has not been yet reported for any patient under MV, but a higher PaO2/FiO2 ratio seems to be better in the higher PEEP group.

APA, Harvard, Vancouver, ISO, and other styles

37

Lee, Amie Y., and Bonnie N. Joe. Post-Lumpectomy/Post-Radiation Breast. Edited by Christoph I. Lee, Constance D. Lehman, and Lawrence W. Bassett. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190270261.003.0062.

Full text

Abstract:

Mammography is currently the primary imaging modality for post-operative evaluation and surveillance of the conservatively treated breast. Tumor recurrence has been shown to occur at a rate of approximately 1–2% per year, and the goal of imaging surveillance is to detect recurrent and new cancers at the earliest stages while avoiding unnecessary biopsies for characteristically benign findings. The radiologist should be familiar with the expected mammographic appearance and evolution of benign post-lumpectomy/post-radiation change, while also recognizing findings suspicious for residual and recurrent disease. This chapter, appearing in the section on intervention and surgical changes, reviews the key imaging and clinical features, imaging protocols and pitfalls, and clinical recommendations for the post-lumpectomy and post-radiation breast. Topics discussed include the evolution of benign post-surgical/post-radiation findings and the detection of suspicious lesions. The primary emphasis will be on mammographic surveillance. The role of ultrasound and MRI will also be discussed.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!